摘要2022年以来，国家药品监督管理局批准抗新型冠状病毒(简称新冠病毒)小分子药物上市共有6款，其中2款为进口药物：美国辉瑞公司的Paxlovid(奈玛特韦/利托那韦)与默沙东公司的莫诺拉韦；4款为国产药物：真实生物公司的阿兹夫定、君实生物公司的氢溴酸氘瑞米德韦、先声药业的先诺欣(先诺特韦/利托那韦)及众生药业的来瑞特韦。从整体作用机理上看，这些药物通过作用于新冠病毒蛋白酶及RNA依赖性RNA聚合酶来杀死新冠病毒，如能早期应用，可有效控制临床症状或减少并发症发生。本文对国内新批准的这6种抗病毒小分子药物的研究概况进行阐述，供临床参考。

abstractsThe National Medical Products Administration has approved 6 small molecule drugs against novel coronavirus for marketing since 2022, of which 2 are imported drugs: Paxlovid (Nirmatrelvir/Ritonavir) of Pfizer and Molnupiravir of Merck; 4 are domestic products: Azvudine of Real, Deuremidevir Hydrobromide (VV116) of Junshi Biologics, Simnotrelvir/Ritonavir of Simcere pharmaceutical and Leritrelvir of Zhongsheng pharmaceutical. The overall mechanism of action if these drugs is inhibiting protease and RNA-dependent RNA polymerase to eliminate novel coronavirus. If applied early, the clinical symptoms can be effectively controlled and complications can be reduced. In this article, the resent progress of 6 newly approved anti-novel coronavirus small molecular drugs in China is reviewed for reference of clinical application.